TAMPA, FL / ACCESSWIRE / June 22, 2020 / LM Funding America, Inc. (NASDAQ:LMFA) ("LM Funding" or the "Company"), a technology-based specialty finance company, today announced that holders of its warrants exercised such warrants for 1,227,700 common shares at $2.40 per share for total consideration of $2,946,480. The warrants were issued in the company's November 2018 registered unit offering. The receipt of the proceeds increases the Company cash on hand as it continues executing on the strategy of acquiring accounts from Associations.

"The economic disruption caused by the novel coronavirus pandemic has created an opportunity to buy more accounts from Associations," said LM Funding's Chief Executive Officer, Bruce M. Rodgers. "This unexpected cash influx at $2.40 per share will benefit our efforts to assist our community association customers maintain their buildings, effect repairs, and provide amenities to their residents during this time when more owners than usual are facing unemployment and financial hardship caused by the pandemic."

About LM Funding America:

LM Funding America, Inc., together with its subsidiaries, is a technology-based specialty finance company that provides funding to nonprofit community associations (Associations) primarily located in the state of Florida, as well as in the states of Washington, Colorado and Illinois by funding a certain portion of the associations' rights to delinquent accounts that are selected by the Associations arising from unpaid Association assessments.

Forward-Looking Statements:

This press release may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," and "project" and other similar words and expressions are intended to signify forward-looking statements. Forward-looking statements are not guarantees of future results and conditions but rather are subject to various risks and uncertainties. Some of these risks and uncertainties are identified in the company's most recent Annual Report on Form 10-K and its other filings with the SEC, which are available at www.sec.gov. The occurrence of any of these risks and uncertainties could have a material adverse effect on the company's business, financial condition, and results of operations.

Company Contact:

Bruce M. Rodgers, Chairman and CEO
LM Funding America, Inc.
Tel (813) 222-8996
investors@lmfunding.com

SOURCE: LM Funding America, Inc

ReleaseID: 594655

TORONTO, ON / ACCESSWIRE / June 22, 2020 / PJX Resources Inc. (TSXV:PJX) ("PJX") and DLP Resources Inc. ("DLP"), the wholly owned subsidiary of MG Capital Corporation, are pleased to announce the signing of a Letter of Intent ("LOI") to finalize a definitive Option Agreement in relation to PJX's Sullivan-type Lead Zinc Silver DD Property (or the "Property" ) by July 2, 2020.

The DD Property has potential to host a high-grade Sullivan style deposit that is located near Cranbrook, British Columbia, Canada. The Sullivan Deposit occurs at a geological horizon called the Lower-Middle Aldridge Contact or "LMC" horizon. A 1425 metre sub-vertical hole (PAN-18-01) to test a Magnetotelluric (MT) geophysical anomaly stopped short of the LMC horizon.

PJX and DLP believe there is an opportunity to drill this hole to a greater depth and locate the LMC zone and potential Sullivan style mineralization.

The key terms of the Letter of Intent "LOI" are:

DLP to earn a 50% undivided interest in the DD Property by spending $4 million in exploration expenditures and making a total of $250,000 cash payments to PJX over 48 months of the effective date of the agreement.
DLP will have the right to earn an additional undivided 25% interest (75% total interest) by delivering a bankable commercial feasibility study on the Property within 96 months of the effective date of the agreement.
Upon DLP's exercise of the Option and acquisition of a 50% or 75% interest in the Property, as applicable, the parties will enter into a joint venture agreement for the further development of the Property.

Ian Gendall, President of DLP commented "The geology and Sullivan type deposit potential make the DD Property very attractive. No holes have tested the LMC horizon on the Property and the historic holes drilled to test the LMC horizon in vicinity of the DD Property have encountered geology that supports the potential for a Sullivan Type Deposit. The thickness, alteration, and mineralization of the LMC horizon increases and is strongest in historic holes drilled closest to the DD Property. This points to the DD Property as the location with the best potential to host a Sullivan Type deposit in the Panda geological basin".

Ian further commented "Our key advantages are the excellent infrastructure in the region and the knowledge of our consulting geologist, Dave Pighin, P.Geo., who is very familiar with the project geology and has previously consulted on projects and numerous Sullivan style targets in the area. Our focus is to discover world class deposits in locations where they can be brought into production. We greatly appreciate the opportunity to explore the DD Property and work with PJX going forward."

President and CEO of PJX, John Keating commented "We look forward to having the experienced management team and resources of DLP as partners to advance the DD Property. Their approach to mineral exploration is in sync with our values. This partnership also allows PJX to focus resources on additional highly prospective gold and base metal targets on our other properties in the Cranbrook area".

The road accessible DD Property is located approximately 120 km east of the Trail Metallurgical Complex that produced some 8 million tonnes of zinc, 9 million tonnes of lead, and over 285 million ounces of silver from processing Sullivan Mine concentrate. The Sullivan Mine produced concentrate for over 90 years before being closed in 2001.

DD Property Potential

The Sullivan deposit occurs at a geological horizon called the LMC (Lower-Middle Aldridge Contact).
No drill hole has tested the LMC on the DD Property, which is located in a geological region called the Panda Basin that is similar to the Sullivan Basin.
Historical holes drilled to test the LMC horizon around the DD Property have encountered geology that supports the potential for a Sullivan Type Deposit.
The thickness, alteration, and mineralization of the LMC horizon increases in historical holes and becomes strongest the closer they are drilled to the DD Property.
This suggests that the DD Property has the greatest potential to host a Sullivan Type deposit in the Panda Basin.
One 1425-metre-long sub-vertical hole (Pan-18-01), drilled on the DD Property in 2018, stopped short of the LMC horizon, in a gabbro sill rock unit.
The hole is accessible and needs to be extended and drilled through the gabbro sill to test the potential for a Sullivan type deposit at the LMC horizon.
Albite-silica-sericite-garnet alteration is ubiquitous throughout hole Pan-18-01.
Strong pervasive and fracture-controlled quartz-albite-white mica alteration occurs from 1262-1361m, proximal to the upper contact of the lowermost gabbro sill.
These types of alteration are consistent with a geological environment that could host a Sullivan type deposit.
The lowermost gabbro sill has the highest mean concentration of zinc (185 ppm) out of any rock unit in the hole. This is unusually anomalous for gabbro.
A MT conductivity anomaly targeted by PAN-18-01 may be explained by an increase in pyrrhotite in the lowermost gabbro sill intersected from 1361 – 1425m, or may be caused by a conductive source, such as massive sulphide, below the sill.
The anomalous zinc and pyrrhotite in the lowermost gabbro sill may have been absorbed by the gabbro when it intruded zinc and iron rich sediments or a possible Sullivan type massive sulphide body at depth below the sill.

The foregoing geological disclosure has been reviewed and approved by Dave Pighin, P.Geo., Ian Gendall, Pr. Sci. Nat., and John Keating P.Geo. (qualified persons for the purpose of National Instrument 43-101 Standards of Disclosure for Mineral Projects). Mr. Pighin is the consulting geologist for PJX and DLP on the DD Property. Mr. Gendall is the President of DLP. Mr. Keating is the President, Chief Executive Officer and a Director of PJX.

About PJX Resources Inc.

PJX is a mineral exploration company focused on building shareholder value and community opportunity through the exploration and development of mineral resources with a focus on gold and base metals. PJX's properties are located in the historical mining area of Cranbrook and Kimberley, British Columbia. Please refer to our web site http://www.pjxresources.com for additional information.

FOR FURTHER INFORMATION PLEASE CONTACT:

Linda Brennan, Chief Financial Officer
(416) 799-9205
info@pjxresources.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This News Release contains forward-looking statements. Forward looking statements are statements which relate to future events. Forward-looking statements include, but are not limited to, statements with respect to exploration results, the success of exploration activities, mine development prospects, completion of economic assessments, and future gold production. In some cases, you can identify forward-looking statements by terminology such as "may", "appears to", "should", "expects", "plans", "anticipates", believes", "estimates", "predicts", "potential", or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking-statements.

Although PJX has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

SOURCE: PJX Resources Inc.

ReleaseID: 594548

TORTOLA, BVI / ACCESSWIRE / June 22, 2020 / TraceSafe Inc. ("Tracesafe") (CSE:TSF) announced today that Boustead Projects E&C Pte Ltd (Singapore), one of the largest construction firms in Singapore, entered into an arrangement with a local Tracesafe nominee to provide contact tracing solutions to help meet the COVID-Safe Restart Criteria published by the Singapore Building and Construction Authority. This represents the first Enterprise Contact Tracing deployment of the product suite called "AllSafe".

TraceSafe's wearable devices and cloud management software will be deployed at a Boustead construction site to facilitate contact-tracing in the event of positive confirmed cases of COVID-19. Workers who may be exposed can be readily identified by contact tracing records based on proximity of the devices worn by all workers. Social-distancing encroachments are detected and recorded, as well as alarm warnings generated in real-time for site supervisors to take immediate action. Worker assignments and team separations are also facilitated. The first deployment is expected at a select project site, and once the relevant government authority approvals and support are obtained, both parties will work toward expanding the deployment across all project sites.

The arrangement is an example of major enterprise employing TraceSafe contact tracing solutions to help reopen safely using technology to provide a safer work environment. TraceSafe continues to work to win the trust of large, respected companies and governments as part of a broader, long term safety initiative – a social distancing solution for a post-Covid reopening world.

Executive Quote

"We are thrilled that Boustead has agreed to deploy our technology at its worksite for their workers as they reopen. Singapore is one of the most rapidly industrializing countries in the world. We believe that TraceSafe solutions are well suited for this application. We could not be more excited working with Boustead." said Dennis Kwan, CEO of TraceSafe Technologies, Inc. Mr. Kwan added: "A successful proof-of-concept will position TraceSafe as a solution for construction sites and other large-scale enterprises looking to reopen safely."

Pursuant to the arrangement with Boustead, Tracesafe will provide contact tracing and social distancing wearable safety technology to Boustead construction site personnel, provide and install gateway devices at certain entrance/exit and other points around the site and provide cloud services for retrieval of contact tracing data from the tags. On proof-of-concept, the parties agreed to negotiate a definitive agreement for the deployment of Tracesafe's products in all Boustead managed worksites.

About TraceSafe

TraceSafe is a full suite of real-time location management services and contact tracing solutions enabled through advanced low power bluetooth beacons and enterprise cloud management. TraceSafe's leading cloud management solution ensures both user privacy and comprehensive administrative control. TraceSafe's patented contact tracing bracelet has already been deployed in mission critical quarantine applications around the world in partnership with leading governments. In addition to their government work, TraceSafe is developing leading edge solutions for Enterprise, Healthcare, and large-scale venue management.

For further information, please contact:

Wayne Lloyd, CEO
+1 604 629-9975
wayne@tracesafe.io

Alan Tam, CFO
+1 604 377‐7575
alantamca@gmail.com

John Costigan
+1 604 620-8589
jcostigan@ecmbcapital.com

The Canadian Securities Exchange has in no way approved or disapproved the contents of this news release.

Statements in this news release may contain forward-looking statements that are based on Tracesafe's expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to expectations regarding the TRACEsafe assets, future business plans and relationships, future developments in respect of COVID-19 and solutions adopted in response to the virus, the deployment of the Tracesafe technology at additional Boustead sites and the execution of a definitive agreement . Although Tracesafe believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict, including the suitability of our products to help businesses and governments reopen, competition, the spread or containment of COVID-19 and government responses thereto and general economic and market conditions . Therefore, outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Tracesafe undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.

SOURCE: TraceSafe Inc.

ReleaseID: 594695

New reimbursed telehealth program to be launched June 2020

SAN CLEMENTE, CA / ACCESSWIRE / June 22, 2020 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally-invasive medical devices to treat obesity and metabolic diseases, today announced a partnership with inHealth Lifestyle Therapeutics (formerly inHealth Medical Services), a Lifestyle Therapeutics company, to launch the ReShapeCare™ virtual health coaching program this month. The new service is tailored to patients under treatment for obesity, those who may have lost continuity of care, and patients pursuing weight loss surgery and medically supervised weight loss programs. ReShapeCare will enable bariatric surgeons and physicians to optimize management of their patients' care by providing a turn-key, personalized service proven to improve treatment and health outcomes for obesity and associated chronic disease while reducing administrative encumbrances.

"At a time when providers are grappling with the impact of COVID-19 on their patients and practices, we are accelerating our plans to offer an outcomes-focused, high-touch virtual service that enhances patient engagement between required practice visits and is adaptable to their daily lives," said Bart Bandy, CEO and President, ReShape Lifesciences. "We selected inHealth as our chosen provider based on the high quality of their coaches, their exceptional telehealth-enabled platform with a unique reimbursement system for practices, and the strong body of clinical research that proves their method works. Emerging from the effects of this pandemic and recognizing how all of our lives may be changed moving forward, we are excited to introduce this progressive lifestyle centered program that will assist healthcare providers in empowering their patients throughout their weight loss journey."

ReShapeCare is a live, telehealth-based coaching program that provides online weight loss coaching and lifestyle therapy for patients affected by obesity and its associated comorbid conditions such as hypertension and diabetes. Through the service, patients are matched with a dedicated, certified health coach and enjoy one-on-one video sessions with exclusive access to validated educational resources. The service must be prescribed by a physician, can be customized to their practice, and is covered by most insurance plans.

Published clinical studies demonstrate that virtual health coaching leads to more adherent patients and more successful weight loss outcomes. In a 2017 study published in the Journal of Telemedicine and Telecare[i], 69.2% of patients achieved weight loss with a 12-week telemedicine-based weight loss program versus just 8% in the control group that received initial instructions and recommendations although they also had access to the same virtual platform and devices throughout the 12 weeks.

Rashmi S. Mullur, MD, Chief of Telehealth at the VA Greater Los Angeles, endocrinologist at UCLA Health and an investigator on the study, said, "Our study demonstrated the clinical benefit of telehealth-based coaching for improved weight loss. We were able to increase patient access, via video visits, and elevate the level of care we can provide. Our model showed that this approach increases patient adherence and motivation, and allows for greater, shared decision-making responsibility between providers and their patients to reach their health goals."

ReShapeCare acts as a seamless extension of a healthcare provider's practice, driving new revenue at a time when many physicians are bracing for the opposite. The program can be customized to support existing programs of care and provides HIPAA-compliant dashboard reports for the individual medical supervision of enrolled patients. ReShapeCare will be available as a pre- and post-operative service and is appropriate for all bariatric surgery and medically supervised weight loss patients.

"Medical device innovators like ReShape Lifesciences understand that without proper outpatient care and support, a patient's health goals are at risk. To ensure that patients maintain their weight loss, and manage or reverse their chronic disease, we must treat the major underlying cause of that disease: their lifestyle," said Aubrey Jenkins, Co-Founder and President, inHealth Lifestyle Therapeutics. "Our Lifestyle Therapeutics are a perfect complement to the ReShape Lifesciences mission, extending the care their providers deliver and enveloping their patients with a whole health solution that works."

For those providers interested in learning more, please email customerservice@reshapelifesci.com. For more information on ReShape Lifesciences visit www.reshapelifesciencs.com. For more information on inHealth and its work with private practices and corporate partners, visit www.inhealthonline.com.

About inHealth Lifestyle Therapeutics

inHealth is a Lifestyle Therapeutics company with a mission to unlock the human potential for preventing and reversing chronic disease. Our clinically validated, virtual solutions are scientifically proven to activate and sustain long-term patient outcomes, and delivered by trained, certified health coaches. Our Lifestyle Therapeutics can be prescribed by physicians, covered by most insurance, and delivered through our partnerships with clinicians, health plans, employers, and medical devices and digital health innovators. Like our services, we are a virtual company with team members all over the U.S., and we are hiring. To learn more, visit www.inhealthonline.com.

About ReShape Lifesciences Inc.

ReShape Lifesciences™ is a medical device company focused on technologies to treat obesity and metabolic diseases. The FDA-approved LAP-BAND® Adjustable Gastric Banding System is designed to provide minimally invasive long-term treatment of severe obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery, and is intended to enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: risks related to the effects of the COVID-19 outbreak on our results of operations, financial condition or liquidity; risks and uncertainties related to our acquisition of the LAP-BAND system; our ability to continue as a going concern if we are unable to improve our operating results or obtain additional financing; risks related to ownership of our securities as a result of our delisting from the Nasdaq Capital Market; our proposed ReShape Vest product may not be successfully developed and commercialized; our limited history of operations; our losses since inception and for the foreseeable future; the competitive industry in which we operate; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for our ReShape Vest and any modifications to our LAP-BAND system; physician adoption of our products; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in our annual report on Form 10-K filed April 30, 2020. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.

CONTACTS:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

ReShape Lifesciences Marketing Contact:
Diane Utzman-O'Neill
Sr. Director Marketing
952-460-0171
dutzman-oneill@reshapelifesci.com

inHealth Lifestyle Therapeutics Contact:
Amanda Guisbond
Director of Marketing and Communications
inHealth Lifestyle Therapeutics
aguisbond@inhealthonline.com

[i] Alencar, M. et al. Journal of Telemedicine and Telecare. "The efficacy of a telemedicine-based weight loss program with video conference health coaching support." 6 November 2017. DOI: 10.1177/1357633X17745471

SOURCE: ReShape Lifesciences Inc.

ReleaseID: 594601

MIDLAND, VA / ACCESSWIRE / June 22, 2020 / Easi-Set Worldwide, a precast industry product licensing leader and subsidiary of publicly-traded Smith-Midland, Corp. (OTCQX:SMID), product announcement.

In June 2020, the U.S. Patent office issued a new utility patent to Easi-Set Worldwide for its prefabricated building façade panel advancement, related to energy code compliance improvement with corresponding cost and material reductions. The addition of this patent further bolsters Easi-Set's extensive portfolio of intellectual property and provides it licensed producers another customer-oriented performance feature. The patent provides for manufacturing exterior cladding panels having pre-determined thermal and structural performances.

Easi-Set licensed SlenderWall cladding producers can now provide customers (developers, architects, façade consultants, contractors, engineers) envelope panels whose thermal performance is tied closely to the requirements of the North American climatic zones as defined in the current International Energy Conservation Code. The adjustable feature is a direct result of extensive third party panel thermal testing in accordance with ASTM C1363 Thermal Performance of building Materials and Envelope Assemblies by Means of a Hot Box Apparatus. The panel's specific thermal and structural performance is achieved through a predetermined combination of thermal break dimension, depth of closed-cell foam insulation and architectural-concrete-to-stud-frame fastener design.

This unique composite cladding system is 66% lighter than traditional architectural precast and has improved thermal qualities. It is fully compliant with current building codes including fire and seismic requirements. The system is licensed for manufacture to qualified precast concrete companies across North America by Easi-Set Worldwide, a leading product line developer in the precast concrete industry.

"The issuance of this patent maintains Easi-Set's licensed producers' unique position in the market by offering new inherent product performance advantages," stated Art Miles, Easi-Set President. "Our producer partners have very tangible advantages to offer their clients."

To learn more about using SlenderWall for your next project, or to inquire about licensing opportunities, contact us at (540) 439-8911, info@easiset.com

SOURCE: Smith-Midland Corporation

ReleaseID: 594475

JACKSON CENTER, PA / ACCESSWIRE / June 22, 2020 / Halberd Corporation (OTC PINK:HALB) announced the appointment of Dr. Patricio F. Reyes to the position of Chief Technical Officer effective immediately. He will report to Halberd's new Chairman, President and CEO, William A. Hartman and is currently the Chief Medical Officer of the NFL's Retired Players Association (NFL RPA).

Dr. Reyes will head up Halberd Corporation's efforts in the development of a treatment to eradicate Covid-19 and potential mutations of the coronavirus. On June 12, 2020 Dr. Reyes, presented a talk titled "The Neurological Complications of Covid-19" at an international virtual conference, "TBI Conference, Coronavirus and the Nervous System" and it was recently announced he had joined Halberd's Scientific Advisory Board – previously announced in the Company's June 9, 2020 press release.

Dr. Reyes, MD, FAAN, a board certified neurologist and neuropathologist, is Chief Medical Officer and Chair of Scientific & Medical Board of the Retired NFL Players Association.

William A. Hartman, Chairman, President and CEO of Halberd Corporation stated, "Dr. Reyes is an extremely talented and accomplished medical professional, with extensive domestic and international connections throughout the medical community. We are fortunate that he has agreed to join Halberd Corporation as its Chief Technical Officer." Mr. Hartman continued, "We will alert the public to Dr. Reyes' future presentations, particularly those related to COVID-19 and/or our efforts in eradicating it."

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com

Twitter: @HalberdC

AboutHalberd, Inc.

Halberd, Inc. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing Covid-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus." It also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

ReleaseID: 594685

Change represents evolving board capabilities as Tetra enters next stage of its corporate development

OTTAWA, ON / ACCESSWIRE / June 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a bio-pharmaceutical company engaged in cannabinoid-derived drug discovery and development, today announces the departure of one of its members of the Board of Directors (the "Board).

The Tetra Board has received notification that Mr. Gregory Drohan has resigned from the Board effective immediately. The Board would like to thank Mr. Drohan who was previously the President of Church and Dwight Canada, for his contributions to Tetra over the past 2.5 years. He has helped to shape Tetra from a start-up company to an operating Biotechnology company with a rich pipeline of patent protected products. Dr. Bill Cheliak, Chairman of the Board said that, "Greg brought his many years of corporate experience in consumer and OTC medicinal products to help Tetra build a solid foundation to help us stage our next phase of development and growth. It has been my pleasure to work closely with Greg as a valuable member of the Board. He has played a significant role guiding the company through its formative years."

"On behalf of the Board, we'd like to thank Greg for his important contributions to Tetra. His vast corporate experience and leadership skills contributed significantly to building the vision and mission of Tetra Bio-Pharma," said Dr. Guy Chamberland, Chief Executive Officer, Chief Regulatory Officer and Board member. "Looking ahead, Dr. Cheliak and I are preparing Tetra for the next stage of value. Our portfolio of innovative products is unique and represents the solid foundation for a biopharmaceutical company."

The Board has undertaken a process to expand the number of directors on the Board in order to better position the Board to lead the Company in its next growth phase. As a first step, the Board intends to appoint 2 additional directors with relevant expertise in the biotechnology industry. The Board has already identified suitable candidates and hopes to announce appointments in the coming weeks.

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSXV:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:

Alpha Bronze, LLC
Mr. Pascal Nigen
Phone: + 1 (646) 255-0433
tetra@alphabronze.net

Media Contact:

Energi PR
Ms. Carol Levine APR, FCPRS
Phone: + 1 (416) 425-9143 ext. 226
Mobile: + 1 (514) 703-0256
carol.levine@energipr.com

SOURCE: Tetra Bio-Pharma

ReleaseID: 594688

Ausenco to conduct an upgrading study on the Kidd concentrator in connection with the Wasamac gold project
Study constitutes Phase 1 of MOU between Monarch and Glencore Canada (see press release dated May 14, 2020)
Study results expected by October 2020

MONTREAL, QUEBEC / ACCESSWIRE / June 22, 2020 / MONARCH GOLD CORPORATION ("Monarch" or the "Corporation") (TSX:MQR)(OTC PINK:MRQRF)(FRANKFURT:MR7) is pleased to announce that it has retained Ausenco Engineering Canada Inc. ("Ausenco") to conduct an upgrading study on the Kidd concentrator in connection with the potential use of the concentrator to treat the ore mined from the Wasamac gold project. The study constitutes Phase 1 of the memorandum of understanding ("MOU") recently signed with Glencore Canada.

As indicated in the May 14 press release, under Phase 1 of the MOU, Monarch is to launch a study on upgrading all or part of the Kidd concentrator and related infrastructure with a view to shipping the ore from the Wasamac property to the concentrator by railway for processing and transformation into dore bars. The upgrading study is expected to be completed by October 2020.

The study mandate calls for Ausenco to execute the study in two distinct phases. Phase I will focus on developing high-level costs and financials for two practical project options, whole ore leach and flotation leach, and Phase II will develop the preferred option to a pre-feasibility study level.

"We are excited to be working with an engineering firm like Ausenco, which has produced numerous solid studies and developed successful large mining projects around the globe, including recent and relevant benchmark projects such as Moose River Gold (Nova Scotia)," said Jean-Marc Lacoste, President and Chief Executive Officer of Monarch. "Ausenco has a strong track record of delivering project studies that go the extra step in optimizing the project economics."

"Ausenco has a project development ethos centred on cost-effective process and rail design coupled with efficient delivery, driving strong project economics and return on shareholder investment. We intend to apply that ethos to provide a differentiated approach for the Wasamac project, one that extracts the maximum value for Monarch and sets the stage to move from the upgrading study into project execution and commercial production," said Garry Warren, President North America Project Delivery of Ausenco.

Quality control and qualified person

The technical and scientific content of this press release has been reviewed and approved by Marc-André Lavergne, P.Eng., the Corporation's qualified person under National Instrument 43‑101.

Disclaimer

For confidentiality reasons, Monarch reserves the right to not disclose the results of the study on the Kidd concentrator.

ABOUT AUSENCO

Ausenco is a global company redefining what's possible. Our team is based across 26 offices in 14 countries, with projects in over 80 locations worldwide. Combining our deep technical expertise with a 30-year track record, we provide innovative, value-add consulting and engineering studies and project delivery, asset operations and maintenance solutions to the mining & metals, oil & gas and industrial sectors.

ABOUT MONARCH GOLD CORPORATION

Monarch Gold Corporation (TSX: MQR) is an emerging gold mining company focused on becoming a 100,000 to 200,000 ounce per year gold producer through its large portfolio of high-quality projects in the Abitibi mining camp in Quebec, Canada. The Corporation currently owns over 315 km² of gold properties (see map), including the Wasamac deposit (measured and indicated resource of 2.6 million ounces of gold, which includes proven and probable reserves of 1.8 million ounces of gold), the Beaufor, Croinor Gold (see video), and McKenzie Break advanced projects, the Camflo and Swanson exploration projects, and the Camflo and Beacon mills. It also offers custom milling services out of its 1,600 tonne-per-day Camflo mill.

Forward-Looking Statements

The forward-looking statements in this press release involve known and unknown risks, uncertainties and other factors that may cause Monarch's actual results, performance and achievements to be materially different from the results, performance or achievements expressed or implied therein. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this press release.

FOR MORE INFORMATION:

Jean-Marc Lacoste
1-888-994-4465
President and Chief Executive Officer
jm.lacoste@monarquesgold.com

Mathieu Séguin
1-888-994-4465
Vice President, Corporate Development
m.seguin@monarquesgold.com

Elisabeth Tremblay
1-888-994-4465
Senior Geologist – Communications Specialist
e.tremblay@monarquesgold.com

www.monarquesgold.com

SOURCE: Monarch Gold Corp.

ReleaseID: 594498

DURHAM, NC / ACCESSWIRE / June 22, 2020 / Heat Biologics, Inc. ("Heat") (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that the first patient has been treated in the Company's first-in-human Phase 1 clinical trial evaluating PTX-35, the first antibody product candidate developed by Heat Biologics' Pelican Therapeutics subsidiary.

This first-in-human study is expected to enroll up to 30 patients with advanced solid tumors refractory to standard of care. Eligible patients will be enrolled to receive PTX-35 every two weeks until disease progression. Escalating dose levels of PTX-35 will be explored until optimal immunological dose or maximum tolerated dose is established. The objectives of the study include safety evaluation, determination of the recommended Phase 2 dose as well as exploratory analyses of clinical benefit and immunological effect of PTX-35. This trial is supported by a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

Jeff Wolf, CEO of Heat Biologics, commented, "This is an important milestone as we advance our first antibody product candidate into clinical development. I am very pleased with our team's effort in accelerating the development of PTX-35 as well as the speed of execution to initiate our first-in-human study following FDA clearance of our Investigational New Drug (IND) Application. I believe that PTX-35, our potential first-in-class T-cell co-stimulatory antibody, will offer a differentiated approach to benefit cancer patients."

About PTX-35

PTX-35 is a novel, potential first-in-class antibody T-cell co-stimulator targeting TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells. TNFRSF25 agonism leads to activation of antigen-experienced memory CD8+ T cells, which are instrumental for tumor destruction. Preclinical studies have demonstrated that PTX-35, in combination with antigen-driven immunotherapies, resulted in enhanced anti-tumor properties, including potent proliferation of antigen-specific T cells, production of effector cytokines and augmented effector immune function. A favorable safety profile was demonstrated in preclinical studies, with no deleterious cytokine release in mice, non-human primates or in vitro human immune cells.

A $15.2 million grant has been awarded by Cancer Prevention and Research Institute of Texas (CPRIT) to support the pre-clinical development, manufacturing and Phase 1 clinical development for PTX-35.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. Multiple product candidates in development leveraging the gp96 platform, including HS-110 which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial. For more information, please visit www.heatbio.com.

Forward Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 on our current expectations and projections about future events. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectation, and assumptions and include statements such as the expected enrollment in the trial, the potential of PTX-35 as a first-in-class antibody T-cell co-stimulator, and PTX-35 offering a differentiated approach to benefit patients. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including, the ability to successfully enroll and complete the first-in-human clinical trial of PTX-35 in solid tumors, the ability of Heat's therapies to perform as designed, to demonstrate safety and efficacy, as well as results that are consistent with prior results, the ability to enroll patients and complete the clinical trials on time and achieve desired results and benefits, Heat's ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, the ability of Heat together with researchers at the University of Miami to develop a proprietary COVID-19 vaccine, regulatory limitations relating to Heat's ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, Heat's ability to maintain its license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, its ability to continue to maintain its listing on the Nasdaq Capital Market and its ability to retain its key scientists or management personnel, and the other factors described in Heat's most recent annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC, and other subsequent filings with the SEC. The information in this release is provided only as of the date of this release, and Heat undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

ReleaseID: 594675

DIDCOT, UNITED KINGDOM / ACCESSWIRE / June 22, 2020 / Altus Strategies Plc (AIM:ALS)(TSXV:ALTS) (‘'Altus'' or the ‘'Company''), the mining royalty company generating a diversified and precious metal focused portfolio of assets through discovery, investment and acquisition, announces the appointment of Alister Hume as Business Development Manager, with immediate effect.

Mr. Hume will play an integral role for the Company in evaluating and progressing the growing number of potential royalty and project transactions under review. His appointment follows the recent approximately £6.5 million (C$11.2 million) investment by La Mancha Holding S.à r.l. ("La Mancha"), where it acquired a 35.45% stake in Altus. The strategic investment by La Mancha has significantly strengthened the Company's financial position and is enabling Altus to accelerate its growth plans.

Mr. Hume is an experienced investment and business development manager with over a decade of expertise working in private equity and capital markets in the natural resources industry. He has gained international exposure through his roles at Morgans, The Sentient Group and KoBold Metals. He previously held board positions for East Africa Copper Ltd and Meridian Mining S.E. (TSXV: MNO) and holds a Bachelor of Commerce (Finance and Accounting) from Sydney University.

Steven Poulton, Chief Executive of Altus, commented:

"We are delighted to welcome Alister to the team. His appointment reflects our strong growth ambitions and the significant increase in our pipeline of opportunities under review, which is a consequence of La Mancha's strategic investment. Alister has accumulated expertise in project evaluation and transactions from his previous roles in highly respected resource asset management and private equity firms, which will no doubt be invaluable to us. His skills will immediately enhance our ability to review royalty, project and other transaction opportunities. Alister has hit the ground running and is already reviewing a number of potential deals and as such we look forward to updating the market on our progress in due course."

For further information you are invited to visit the Company's website www.altus-strategies.com or contact:

Altus Strategies Plc

Steven Poulton, Chief Executive

Tel: +44 (0) 1235 511 767

E: info@altus-strategies.com

SP Angel (Nominated Adviser)

Richard Morrison / Soltan Tagiev

Tel: +44 (0) 20 3470 0470

SP Angel (Broker)

Abigail Wayne / Richard Parlons

Tel: +44 (0) 20 3470 0471

Yellow Jersey PR (Financial PR & IR)

Georgia Colkin / Charles Goodwin / Henry Wilkinson

Tel: +44 (0) 20 3004 9512

E: altus@yellowjerseypr.com

About Altus Strategies Plc

Altus Strategies is a London (AIM: ALS) and Toronto (TSX-V: ALTS) listed mining royalty company generating a diversified and precious metal focused portfolio of assets. The Company's focus on Africa and differentiated approach, of generating royalties on its own discoveries as well as through financings and acquisitions with third parties, has attracted key institutional investor backing. The Company engages constructively with all stakeholders, working diligently to minimise its environmental impact and to promote positive economic and social outcomes in the communities where it operates. For further information, please visit www.altus-strategies.com.

Cautionary Note Regarding Forward-Looking Statements

Certain information included in this announcement, including information relating to future financial or operating performance and other statements that express the expectations of the Directors or estimates of future performance constitute "forward-looking statements". These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include without limitation the completion of planned expenditures, the ability to complete exploration programmes on schedule and the success of exploration programmes. Readers are cautioned not to place undue reliance on the forward-looking information, which speak only as of the date of this announcement and the forward-looking statements contained in this announcement are expressly qualified in their entirety by this cautionary statement.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. The forward-looking statements contained in this announcement are made as at the date hereof and the Company assumes no obligation to publicly update or revise any forward-looking information or any forward-looking statements contained in any other announcements whether as a result of new information, future events or otherwise, except as required under applicable law or regulations.

TSX Venture Exchange Disclaimer

Neither the TSX Venture Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

Market Abuse Regulation Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR") until the release of this announcement.

**END**

SOURCE: Altus Strategies PLC

ReleaseID: 594708